In June of this year I finally completed more than a year of gruelling treatment for breast cancer, which started with a double mastectomy and continued with various types of chemotherapy. I will be taking [more]
PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future [more]
Most people carrying harmful BRCA mutations only find out after they are diagnosed with cancer, and often not even then. Population screening is costly and the results can be hard to interpret. But should we [more]
Over the past decade, genetic testing for rare inherited mutations, such as BRCA1 and BRCA2 mutations, has been successfully incorporated into clinical practice. Next-generation sequencing of cancer-susceptibility genes and entire tumour genomes has transformed cancer [more]